<DOC>
	<DOC>NCT02597868</DOC>
	<brief_summary>A multi-sites study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine therapy, in metastatic breast cancer patients with HR-positive &amp; HER2-negative after capecitabine-base chemotherapy.</brief_summary>
	<brief_title>A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)</brief_title>
	<detailed_description>capecitabine-base chemotherapy must be first-line chemotherapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Signed informed consent The age is Above 18 years of age, &lt;70 years old HRpositive &amp; HER2negative Metastatic breast cancer,incurable. No prior chemotherapy for metastatic recurrence, if there is disease progression within 6 months after the end of the adjuvant chemotherapy, adjuvant chemotherapy as firstline treatment for metastatic lesions Eastern Cooperative Oncology Group performance status (ECOG PS)=0~1 The basic function of normal bone marrow Functions of liver and kidney is normal Expectation of life is more than 3 months Agreed to take contraceptive measures during treatment Previous toxicity was not recovered to 01 degrees Central nervous system metastasis Pregnancy or lactation There are uncontrolled infection, myocardial infarction, thrombosis, etc. There are uncontrolled chronic diseases such as diabetes, hypertension, peptic ulcer, chronic hepatitis, mental disease; Researchers believe that is not suitable for the study Patients with other malignant tumor history, except the healed skin basal cell carcinoma and carcinoma of uterine cervix; Bilateral breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>therapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>breast cancer</keyword>
</DOC>